title: Weekly intravenous nanoparticle albumin-bound paclitaxel for elderly patients with stage IV non-small-cell lung cancer: a series of 20 cases.
abstract: The purpose of this study was to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel as a rescue regimen in the treatment of patients with advanced non-small-cell lung cancer. We retrospectively reviewed the medical records of 20 patients with stage IV non-small-cell lung cancer. The patients had progressive disease after standard antitumor therapy and subsequently received intravenous albumin-bound paclitaxel at the dose of 100 mg/m(2) in weekly schedule. Cumulative findings showed that the overall response rate was 30.0%, the disease control rate amounted to 40%, and the 1 year survival rate was 30%. In addition, the median time to progression and the median survival time reached 5 and 10 months, respectively. Meanwhile, no severe hypersensitivity reactions and grade 4 adverse effects were reported. In summary, weekly-administered albumin-bound paclitaxel seems to be an effective and safe regimen for elderly patients with stage IV non-small-cell lung cancer who were refractory to conventional therapy.
authors.affiliation: Department of Medical Oncology, the First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Zheng
authors.forename: Yu
authors.initials: Y
authors.lastname: Yao
authors.forename: Kejun
authors.initials: K
authors.lastname: Nan
keywords: albumin-bound; nanoparticles; non-small-cell lung cancer; paclitaxel
references.citation: N Engl J Med. 2005 Jul 14;353(2):123-32
references.pmid: 16014882
references.citation: Clin Breast Cancer. 2007 Dec;7(11):850-6
references.pmid: 18269774
references.citation: Clin Cancer Res. 2006 Feb 15;12(4):1317-24
references.pmid: 16489089
references.citation: Ann Oncol. 2006 Aug;17(8):1263-8
references.pmid: 16740598
references.citation: Clin Cancer Res. 2002 May;8(5):1038-44
references.pmid: 12006516
references.citation: J Clin Oncol. 1995 Jan;13(1):180-90
references.pmid: 7799018
references.citation: Cancer Res. 1999 Apr 1;59(7):1454-7
references.pmid: 10197613
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Eur Respir J. 2001 Dec;18(6):1059-68
references.pmid: 11829087
references.citation: Lancet. 1993 Jul 3;342(8862):19-21
references.pmid: 8100290
references.citation: Breast. 2011 Oct;20(5):468-74
references.pmid: 21843943
references.citation: Br J Cancer. 2004 Jan 26;90(2):304-5
references.pmid: 14974481
references.citation: Eur J Cancer. 2001 Sep;37(13):1590-8
references.pmid: 11527683
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: J Thorac Oncol. 2009 Dec;4(12):1537-43
references.pmid: 19887966
references.citation: J Clin Oncol. 2005 May 1;23(13):2926-36
references.pmid: 15728229
references.citation: CA Cancer J Clin. 1988 Jan-Feb;38(1):5-22
references.pmid: 3123025
references.citation: Oncologist. 1999;4(5):408-16
references.pmid: 10551557
references.citation: Am J Physiol Lung Cell Mol Physiol. 2003 Jan;284(1):L187-96
references.pmid: 12471015
references.citation: N Engl J Med. 2002 Jan 10;346(2):92-8
references.pmid: 11784875
references.citation: Cancer. 1995 Jan 1;75(1 Suppl):191-202
references.pmid: 8000996
references.citation: J Clin Oncol. 2005 Nov 1;23(31):7794-803
references.pmid: 16172456
references.citation: Eur J Cancer. 1997 Dec;33(14):2313-4
references.pmid: 9616273
references.citation: J Clin Oncol. 2005 Nov 1;23(31):7785-93
references.pmid: 16258082
references.citation: J Thorac Oncol. 2010 Jun;5(6):852-61
references.pmid: 20521351
references.citation: Lung Cancer. 2011 Jan;71(1):3-10
references.pmid: 20951465
references.citation: J Clin Oncol. 2005 Sep 1;23(25):6019-26
references.pmid: 16135470
references.citation: Agents Actions. 1977 Mar;7(1):63-7
references.pmid: 67784
references.citation: Mol Biol Cell. 2003 Oct;14(10):3977-88
references.pmid: 14517312
references.citation: J Clin Oncol. 2008 Oct 1;26(28):4617-25
references.pmid: 18678835
references.citation: J Clin Oncol. 1990 Jul;8(7):1263-8
references.pmid: 1972736
references.citation: Adv Drug Deliv Rev. 2008 May 22;60(8):876-85
references.pmid: 18423779
references.citation: J Clin Oncol. 2008 Feb 1;26(4):639-43
references.pmid: 18235124